博晖创新(300318.SZ)子公司获得静注人免疫球蛋白临床试验批准

Core Viewpoint - The company announced that its subsidiary, Guangdong Weirun Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of intravenous immunoglobulin [1] Group 1: Company Developments - Guangdong Weirun has been granted a Clinical Trial Approval Notice for intravenous immunoglobulin, allowing it to commence clinical trials [1] - The intravenous immunoglobulin is already marketed and sold both domestically and internationally [1] Group 2: Industry Context - Several domestic blood product companies, including the company's subsidiary Bohui Biopharmaceutical (Hebei) Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shandong Taibang Biological Products Co., Ltd., and Hualan Biological Engineering Co., Ltd., have intravenous immunoglobulin products available in the market [1]